Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$5.67 USD
+0.73 (14.78%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.69 +0.02 (0.35%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AQST 5.67 +0.73(14.78%)
Will AQST be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates
Other News for AQST
New 52 Week Closing High appears for AQST after 14.78% move
12 Health Care Stocks Moving In Friday's Intraday Session
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday
Is AQST gaining bullish strength? 1,2,3 Pullback Bullish shows up after gaining 2.28%
AQST falls 0.82% on September 17, leaving the technical picture intact